AGÕæÈ˹ٷ½

UBS AG is offering Contingent Income Auto-Callable Securities linked to the common stock of PayPal Holdings, Inc. (PYPL). The notes are senior unsecured obligations of UBS AG London Branch, priced at $1,000 per security, with expected issuance on 16 July 2025 and maturity on or about 14 July 2028 (�36 months).

Coupon mechanics: investors receive a fixed contingent payment of $27.875 per quarter (�11.15 % p.a.) for any determination date on which PYPL’s closing price is at least 65 % of the initial price (“downside threshold�). If, on any determination date other than the final one, PYPL closes at or above 100 % of the initial price (“call threshold�), the notes are automatically redeemed for $1,000 + the current coupon.

Principal repayment: � If the final price on 11 July 2028 is �65 % of the initial price, holders receive principal plus the final coupon. � If it is <65 %, UBS will pay a cash value equal to the percentage decline in PYPL, exposing investors to a 1-for-1 loss below the threshold and up to 100 % loss of principal. There is no upside participation in PYPL shares.

Key economics & costs: � Estimated initial value: $937.30 � $967.30 (3.3 %-6.3 % below issue price), reflecting dealer margins, hedging and funding costs. � Up-front fees total 2.25 % of principal (1.75 % sales commission, 0.50 % structuring fee). � Securities will not be listed; UBS Securities LLC intends, but is not obligated, to provide a secondary market.

Risk highlights: investors face (i) issuer credit risk of UBS AG, (ii) equity risk in PYPL, (iii) liquidity risk given the unlisted nature, (iv) early-call reinvestment risk, and (v) tax uncertainty; the notes are treated as prepaid derivatives with ordinary-income coupons.

Investor profile: suitable only for sophisticated investors who can tolerate loss of principal, limited upside, and illiquidity in exchange for above-market contingent income.

UBS AG is offering Contingent Income Auto-Callable Securities linked to the common stock of PayPal Holdings, Inc. (PYPL). The notes are senior unsecured obligations of UBS AG London Branch, priced at $1,000 per security, with expected issuance on 16 July 2025 and maturity on or about 14 July 2028 (�36 months).

Coupon mechanics: investors receive a fixed contingent payment of $27.875 per quarter (�11.15 % p.a.) for any determination date on which PYPL’s closing price is at least 65 % of the initial price (“downside threshold�). If, on any determination date other than the final one, PYPL closes at or above 100 % of the initial price (“call threshold�), the notes are automatically redeemed for $1,000 + the current coupon.

Principal repayment: � If the final price on 11 July 2028 is �65 % of the initial price, holders receive principal plus the final coupon. � If it is <65 %, UBS will pay a cash value equal to the percentage decline in PYPL, exposing investors to a 1-for-1 loss below the threshold and up to 100 % loss of principal. There is no upside participation in PYPL shares.

Key economics & costs: � Estimated initial value: $937.30 � $967.30 (3.3 %-6.3 % below issue price), reflecting dealer margins, hedging and funding costs. � Up-front fees total 2.25 % of principal (1.75 % sales commission, 0.50 % structuring fee). � Securities will not be listed; UBS Securities LLC intends, but is not obligated, to provide a secondary market.

Risk highlights: investors face (i) issuer credit risk of UBS AG, (ii) equity risk in PYPL, (iii) liquidity risk given the unlisted nature, (iv) early-call reinvestment risk, and (v) tax uncertainty; the notes are treated as prepaid derivatives with ordinary-income coupons.

Investor profile: suitable only for sophisticated investors who can tolerate loss of principal, limited upside, and illiquidity in exchange for above-market contingent income.

UBS AG is offering Contingent Income Auto-Callable Securities linked to the common stock of PayPal Holdings, Inc. (PYPL). The notes are senior unsecured obligations of UBS AG London Branch, priced at $1,000 per security, with expected issuance on 16 July 2025 and maturity on or about 14 July 2028 (�36 months).

Coupon mechanics: investors receive a fixed contingent payment of $27.875 per quarter (�11.15 % p.a.) for any determination date on which PYPL’s closing price is at least 65 % of the initial price (“downside threshold�). If, on any determination date other than the final one, PYPL closes at or above 100 % of the initial price (“call threshold�), the notes are automatically redeemed for $1,000 + the current coupon.

Principal repayment: � If the final price on 11 July 2028 is �65 % of the initial price, holders receive principal plus the final coupon. � If it is <65 %, UBS will pay a cash value equal to the percentage decline in PYPL, exposing investors to a 1-for-1 loss below the threshold and up to 100 % loss of principal. There is no upside participation in PYPL shares.

Key economics & costs: � Estimated initial value: $937.30 � $967.30 (3.3 %-6.3 % below issue price), reflecting dealer margins, hedging and funding costs. � Up-front fees total 2.25 % of principal (1.75 % sales commission, 0.50 % structuring fee). � Securities will not be listed; UBS Securities LLC intends, but is not obligated, to provide a secondary market.

Risk highlights: investors face (i) issuer credit risk of UBS AG, (ii) equity risk in PYPL, (iii) liquidity risk given the unlisted nature, (iv) early-call reinvestment risk, and (v) tax uncertainty; the notes are treated as prepaid derivatives with ordinary-income coupons.

Investor profile: suitable only for sophisticated investors who can tolerate loss of principal, limited upside, and illiquidity in exchange for above-market contingent income.

Form 4 filing for Y-mAbs Therapeutics (YMAB) discloses that director Laura Hamill received new equity awards on 30 June 2025.

• Restricted Stock Units: 25,080 RSUs granted at no cost. The award vests in full on the earlier of 12 months after grant or immediately before the 2026 annual shareholder meeting, subject to continued service.
• Stock Options: 33,450 options with a US$4.51 exercise price, expiring 30 June 2035. Vest in equal monthly instalments over one year and become exercisable upon vesting.
• Post-transaction ownership: Hamill now directly holds 30,905 YMAB common shares and 33,450 vested/unvested options.

The transactions reflect routine director compensation under the 2018 Equity Incentive Plan and do not involve open-market purchases or sales.

Form 4 filing for Y-mAbs Therapeutics (YMAB) discloses that director Laura Hamill received new equity awards on 30 June 2025.

• Restricted Stock Units: 25,080 RSUs granted at no cost. The award vests in full on the earlier of 12 months after grant or immediately before the 2026 annual shareholder meeting, subject to continued service.
• Stock Options: 33,450 options with a US$4.51 exercise price, expiring 30 June 2035. Vest in equal monthly instalments over one year and become exercisable upon vesting.
• Post-transaction ownership: Hamill now directly holds 30,905 YMAB common shares and 33,450 vested/unvested options.

The transactions reflect routine director compensation under the 2018 Equity Incentive Plan and do not involve open-market purchases or sales.

Matson, Inc. (MATX) â€� Insider Form 4 filing

Executive Vice President and President of Matson Logistics, Jerome James Holland, reported the acquisition of 538 shares of Matson common stock on 07/01/2025. The shares were issued as restricted stock units (RSUs) under the company’s 2025 Incentive Compensation Plan at $0.00 cost. The RSUs vest in three equal annual tranches beginning one year from the grant date and include dividend-equivalent rights. Following the grant, Holland’s direct beneficial ownership increases to 3,738 shares. No disposals, derivative transactions, or Rule 10b5-1 plan trades were disclosed.

The filing was submitted individually by the executive, indicating a routine equity incentive award intended to align management and shareholder interests. No other material changes were reported.

Matson, Inc. (MATX) â€� Insider Form 4 filing

Executive Vice President and President of Matson Logistics, Jerome James Holland, reported the acquisition of 538 shares of Matson common stock on 07/01/2025. The shares were issued as restricted stock units (RSUs) under the company’s 2025 Incentive Compensation Plan at $0.00 cost. The RSUs vest in three equal annual tranches beginning one year from the grant date and include dividend-equivalent rights. Following the grant, Holland’s direct beneficial ownership increases to 3,738 shares. No disposals, derivative transactions, or Rule 10b5-1 plan trades were disclosed.

The filing was submitted individually by the executive, indicating a routine equity incentive award intended to align management and shareholder interests. No other material changes were reported.

Matson, Inc. (MATX) â€� Insider Form 4 filing

Executive Vice President and President of Matson Logistics, Jerome James Holland, reported the acquisition of 538 shares of Matson common stock on 07/01/2025. The shares were issued as restricted stock units (RSUs) under the company’s 2025 Incentive Compensation Plan at $0.00 cost. The RSUs vest in three equal annual tranches beginning one year from the grant date and include dividend-equivalent rights. Following the grant, Holland’s direct beneficial ownership increases to 3,738 shares. No disposals, derivative transactions, or Rule 10b5-1 plan trades were disclosed.

The filing was submitted individually by the executive, indicating a routine equity incentive award intended to align management and shareholder interests. No other material changes were reported.

Form 4 filing summary � KeyCorp (KEY), 07/01/2025: Director Barbara R. Snyder converted 35,955 deferred shares (transaction code M) into an equal number of common shares. The conversion increased her directly held common-share position to 71,632 shares. No open-market purchase or sale price was reported because the shares derive from KeyCorp’s Directors� Deferred Share Sub-Plan, where each deferred share is economically equivalent to a common share. Following the transaction, Snyder still holds 177,901 deferred shares that remain subject to the plan. The filing also notes that direct ownership totals include roughly 175 common shares obtained through the June 2025 dividend-reinvestment program, and deferred-share holdings include about 2,765 dividend-equivalent units accrued during the same period. As there was no disposition of shares and the transaction merely settles a long-standing equity award, the impact on KeyCorp’s public float and insider sentiment is modest.